Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
22°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Forte Biosciences, Inc.
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
November 20, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
November 14, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
August 14, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
May 17, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
May 13, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
March 18, 2024
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
December 01, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
November 13, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
August 14, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
August 01, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
May 19, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
May 15, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
March 31, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
January 12, 2023
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
November 14, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
November 14, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
August 15, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
June 07, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
June 07, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
May 16, 2022
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
September 02, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
August 16, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
August 02, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
July 12, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
July 01, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
May 10, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
May 03, 2021
From
Forte Biosciences, Inc.
Via
Business Wire
Tickers
FBRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.